Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
SCRI Oncology Partners- Denver, Denver, Colorado UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Sarah Cannon Research Institute, Nashville, Tennessee Australia
Greenslopes Private Hospital, Greenslopes, Queensland